Wang, Weiqing http://orcid.org/0000-0001-6027-3084
Bain, Stephen C. http://orcid.org/0000-0001-8519-4964
Bian, Fang http://orcid.org/0009-0005-1219-4345
Chen, Rui http://orcid.org/0009-0007-3128-3524
Gabery, Sanaz http://orcid.org/0000-0002-2243-7540
Huang, Shan http://orcid.org/0000-0001-8125-953X
Jensen, Thomas B. http://orcid.org/0000-0002-8920-9374
Luo, Bifen http://orcid.org/0000-0001-7166-278X
Yuan, Guoyue http://orcid.org/0000-0003-0822-6066
Ning, Guang http://orcid.org/0000-0002-5754-7635
,
Funding for this research was provided by:
Novo Nordisk A/S
Article History
Received: 5 October 2023
Accepted: 15 January 2024
First Online: 10 July 2024
Acknowledgements
: Medical writing and editorial support were provided by A. Richold (Apollo, OPEN Health Communications, London, UK) and were funded by Novo Nordisk, in accordance with Good Publication Practice 3 (GPP3) guidelines (). The authors thank the participants, the investigators, all trial site staff and all Novo Nordisk A/S employees involved in the trial. The authors also thank W. Liu of Novo Nordisk A/S for her role in reviewing this manuscript.
: Data will be shared with researchers submitting a research proposal approved by the independent review board. Information on requesting access to datasets can be found at . Data will be made available after research completion and approval of the product and product use in the European Union and the USA. Individual participant data will be shared in datasets in a de-identified and anonymised format, with no limitations on how the data can be used.
: This trial was funded by Novo Nordisk A/S, Søborg, Denmark. The study sponsor was involved in the study design, data collection, analysis and interpretation and the writing of this report.
: SCB received honoraria and teaching and research sponsorship/grants from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, MSD, Novo Nordisk, Pfizer, Sanofi and Takeda. RC and BL are employees and shareholders of Novo Nordisk (China) Pharmaceuticals Co., Ltd. SG and TBJ are employees and shareholders of Novo Nordisk A/S. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All authors made substantial contributions to the conception and design of the trial, acquisition of data and/or the analysis and interpretation of data. All authors had access to the study data, critically reviewed the manuscript and approved the final version to be published. WW, RC, SG, TBJ and BL are guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.